RNAZ
Income statement / Annual
Last year (2025), TransCode Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, TransCode Therapeutics Inc's net income was -$34.66 M.
See TransCode Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$534.86 K
|
$516.75 K
|
$98.61 K
|
$42.47 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$534.86 K
|
-$516.75 K
|
-$98.61 K
|
-$42.47 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$13.42 M
|
$9.62 M
|
$12.26 M
|
$10.23 M
|
$2.75 M
|
$284.46 K
|
$226.31 K
|
$82.53 K
|
| General & Administrative Expenses |
$5.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$301.46 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.77 M
|
$5.51 M
|
$6.64 M
|
$8.33 M
|
$3.35 M
|
$442.15 K
|
$230.56 K
|
$301.46 K
|
| Other Expenses |
$8.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$27.98 M
|
$15.13 M
|
$18.90 M
|
$18.57 M
|
$6.11 M
|
$726.60 K
|
$456.87 K
|
$384.52 K
|
| Cost And Expenses |
$27.98 M
|
$15.66 M
|
$19.42 M
|
$18.67 M
|
$6.15 M
|
$726.60 K
|
$456.87 K
|
$384.52 K
|
| Interest Income |
$79.20 K
|
$684.00
|
$5.29 K
|
$20.41 K
|
$664.00
|
$136.00
|
$34.00
|
$68.92 K
|
| Interest Expense |
$6.62 K
|
$26.81 K
|
$55.90 K
|
$17.56 M
|
$95.07 K
|
$394.57 K
|
$156.97 K
|
$0.00
|
| Depreciation & Amortization |
$114.18 K
|
$534.86 K
|
$516.75 K
|
$98.61 K
|
$42.47 K
|
$0.00
|
$0.00
|
$384.00 K
|
| EBITDA |
-$34.31 M |
-$16.19 M |
-$17.97 M |
-$17.47 M |
-$6.71 M |
-$1.95 M |
-$450.25 K |
-$69.44 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$6.45 M
|
-$1.09 M
|
$872.42 K
|
$1.10 M
|
-$692.26 K
|
-$1.62 M
|
-$150.35 K
|
-$69.44 K
|
| Income Before Tax |
-$34.44 M
|
-$16.75 M
|
-$18.55 M
|
-$17.56 M
|
-$6.84 M
|
-$2.34 M
|
-$607.21 K
|
-$453.44 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$226.07 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$34.66 M
|
-$16.75 M
|
-$18.55 M
|
-$17.56 M
|
-$6.84 M
|
-$2.34 M
|
-$607.21 K
|
-$453.44 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-52.59 |
-47.14 |
-3453.65 |
-73187.37 |
-648 |
-293.76 |
-72 |
-2359.09 |
| EPS Diluted |
-52.59 |
-47.14 |
-3453.53 |
-1080 |
-648 |
-293.76 |
-72 |
-2359.09 |
| Weighted Average Shares Out |
$689.71 K
|
$356.12 K
|
$5.42 K
|
$16.22 K
|
$10.53 K
|
$7.98 K
|
$6.41 K
|
$192.21
|
| Weighted Average Shares Out Diluted |
$689.71 K
|
$356.12 K
|
$5.42 K
|
$16.22 K
|
$10.53 K
|
$7.98 K
|
$6.41 K
|
$192.21
|
| Link |
|
|
|
|
|
|
|
|
